HOME >> MEDICINE >> NEWS
Dopamine may play role in cue-induced craving distinct from its role regulating reward effects

NIDA-supported researchers from Brookhaven National Laboratory and the State University of New York at Stony Brook have found evidence in humans that dopamine plays a role in the conditioned cue response to food. Cuesseeing, smelling, and tasting something enjoyableincrease the desire for the reward without necessarily enhancing the pleasure of the reward itself.

Positron emission tomography (PET) was used to measure changes in dopamine in the brains of 10 healthy adults (eight men and two women) during food and neutral stimulations. Food stimulation consisted of the participants viewing, smelling, and tasting their favorite foods but not actually eating the foods. For neutral stimulation, participants described their family genealogy in detail. Prior to and during food stimulation, participants were instructed to rate their feelings of "hunger," "desire for food," "alertness," "stimulation," and "talkativeness" on a scale of 1 to 10. Participants had fasted 16-20 hours before PET scans were conducted.

Food stimulation caused an increase in dopamine in the dorsal striatum but not in the ventral striatum, where the nucleus accumbens is located. This suggests that dopamine may be involved in food motivation that is distinct from its role in regulating food's reward effects through the nucleus accumbens. Previous research has linked increases in dopamine in the nucleus accumbens, the reward center of the brain, with addiction.

WHAT IT MEANS: The finding that dopamine may play a role in cue-induced effects could have important implications in drug addiction research. Many individuals addicted to drugs, especially cocaine and nicotine, are susceptible to cue-induced cravings. A better understanding of the biological basis of cue-related behaviors may provide better insights in the development of more effective behavioral and pharmacological treatments for drug addiction.


'"/>

Contact: Blair Gately
bgately@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
28-May-2002


Page: 1

Related medicine news :

1. Dopamine key to learning likes and dislikes, says Colorado U. team
2. Its a gamble: Dopamine levels tied to uncertainty of rewards
3. New Findings On Dopamine Receptor Biology: Implications For Mental Illness
4. Breakthrough? Study Finds Dopamine Cannot Be Source Of Pleasure In Brain
5. Brain regions activated by food craving overlap with areas implicated in drug craving
6. Single cocaine exposure boosts both drug craving and avoidance
7. Comfort-food cravings may be bodys attempt to put brake on chronic stress
8. Compounds also present in alcoholic beverages may explain chocolate cravings
9. Drug that curbs nicotine craving may do same for cocaine
10. Patients recovering from depression with talk therapy show a distinct pattern of brain changes
11. Late-onset schizophrenia found to be distinct condition

Post Your Comments:
(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
Cached News: